Articles from Infinity Bio, Inc.

Infinity Bio, a biotechnology company pioneering the MIPSA technology, today announced the appointment of Brian McKelligon as Chief Executive Officer. McKelligon, an accomplished leader with extensive experience building and scaling innovative life sciences platforms, will guide the company's next phase of growth, global expansion, and commercial acceleration of its proprietary MIPSA technology.

Infinity Bio, Inc., a leader in advanced immune system analysis, today announced a new partnership with the Austrian Institute of Technology (AIT) to bring its proprietary antibody reactome profiling platform to researchers throughout Europe. By integrating Infinity Bio’s groundbreaking MIPSA (Molecular Indexing of Proteins by Self-Assembly) technology with AIT’s established immunomics pipeline and clinical infrastructure, the collaboration will accelerate biomarker discovery and translational research in immunology, virology, autoimmunity, and allergy. Infinity Bio, Inc.’s MIPSA technology achieves unmatched breadth and resolution in mapping the molecular targets of immune responses. The company’s current catalog of antigen panels – VirSIGHT, HuSIGHT, and EnviroSIGHT – blend full-length protein and peptide libraries, providing the most in-depth assays for detecting antibodies targeting all human viruses, self-proteins, or environmental antigens (including allergens, non-viral and microbial proteins), respectively, all in a single test.

Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund.

Infinity Bio, Inc. is proud to announce its selection by the TEDDY (The Environmental Determinants of Diabetes in the Young) study to provide comprehensive antibody reactome services for their large cohort. This collaboration marks a significant milestone for Infinity Bio as it continues to advance its mission to deliver cutting-edge immunological insights and solutions.

Infinity Bio, Inc., a biotechnology company specializing in antibody reactome profiling, hosted a special community event aimed at engaging and inspiring Baltimore children with an interest in STEM. The event took place on July 22, 2024, at Infinity Bio’s office and laboratory at 6200 Seaforth Street, Baltimore, MD, and featured various activities designed to spark interest in science and technology.

Infinity Bio, a technology company known for its innovative antibody reactome profiling service, will host an open house event at its state-of-the-art laboratory at 6200 Seaforth Street in Baltimore on July 23, 2024. This event is designed to give members of the local scientific and biotech community an exclusive look at the research and technologies that are driving developments in immunology.

Infinity Bio, Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This platform offers unparalleled depth in immune system analysis, advancing immunology, virology, autoimmunity, and allergy research, providing new disease insights, and discovering new biomarkers and treatments. The MIPSA technology exploits recent advances in high throughput DNA sequencing and DNA synthesis, to create and analyze the most complete panels of immune targets available.